Healthcare Workers Support Psychedelics but Need More Knowledge, Study Finds
Last reviewed and updated: August 20, 2026.
Key Takeaways
| The finding | Surveys consistently show healthcare workers are broadly supportive of psychedelic-assisted therapy but report low confidence in their own knowledge. |
| Why it matters | Clinicians are the first people patients ask, so an informed provider can counsel on risks, set expectations, and refer appropriately. |
| The training gap | Formal psychedelic education is not standard in medical, nursing, or psychology curricula, though certificate programs exist and interest is rising. |
| Growing urgency | With psilocybin advancing toward possible approval and Spravato already in wide use, more providers will encounter these treatments. |
| What to do | Patients should not assume a provider is informed on this topic, and providers can close the gap through continuing education and formal training programs. |
The potential of psychedelics to revolutionize mental health treatment has sparked significant interest, but how prepared are healthcare workers to embrace this emerging field? A recent study reveals a surprising gap: while many healthcare professionals support the use of psychedelics in therapy, most lack the knowledge needed to safely and effectively guide patients through these treatments. This knowledge gap raises important questions about the future of psychedelic therapy in mainstream healthcare.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Broad Healthcare Worker Support but Limited Understanding
The study found that a majority of healthcare workers see value in psychedelics for treating conditions like depression, PTSD, and anxiety. This enthusiasm reflects the growing body of research highlighting the transformative potential of compounds such as psilocybin and MDMA. Yet, most professionals admitted they are unfamiliar with how these therapies work, the specific conditions they can treat, or how to incorporate them into practice.
Most patients assume their own doctor can navigate this emerging field. The study suggests that even among well-meaning professionals, a lack of formal training could limit access to effective care.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
How Will Lack of Education Have an Impact?
Here’s a breakdown of the areas where healthcare workers need more understanding regarding psychedelics and the potential impact of these knowledge gaps:
| Area of Understanding | What They Need to Understand | Potential Impact of Knowledge Gap |
|---|---|---|
| Mechanism of Action | Understanding how psychedelics like psilocybin and MDMA affect the brain and mental health. | Misinterpretation of how psychedelics work, leading to incorrect advice or treatment. |
| Appropriate Conditions for Use | Knowing which mental health conditions (e.g., PTSD, depression) are most effectively treated by psychedelics. | Misdiagnosis or inappropriate treatment recommendations. |
| Patient Screening | Identifying which patients are suitable candidates, considering medical history and mental health risks. | Increased risk of adverse effects for patients with contraindications or vulnerabilities. |
| Dosing Protocols | Understanding safe and effective dosage levels for different therapeutic settings. | Over- or under-dosing, reducing effectiveness or increasing the risk of harm. |
| Management of Emotional Responses | Training to guide patients through intense or challenging experiences during therapy. | Poor patient outcomes due to mishandling of difficult sessions or emotional distress. |
| Integration and Aftercare | Helping patients process and integrate psychedelic experiences into their daily lives. | Missed opportunities for long-term benefits or relapse into old patterns. |
| Legal and Ethical Guidelines | Familiarity with current laws and ethical considerations surrounding psychedelic use in therapy. | Potential legal risks or ethical breaches by healthcare professionals. |
| “Set and Setting” Principles | Creating a therapeutic environment conducive to positive outcomes. | Ineffective sessions due to poorly managed therapeutic environments. |
Where the Gaps Are Widest
- The most significant gaps are in clinical application, such as screening, dosing, and managing emotional responses.
- Without targeted education, healthcare professionals risk undermining patient safety and the credibility of psychedelic therapies.
- Bridging these gaps through training and certification programs could ensure safer, more effective use of psychedelics in mental health care.
Healthcare Workers Support Psychedelics, But Education Is the Missing Piece
The knowledge gap underscores the need for targeted education and training programs for healthcare providers. Psychedelic therapy requires a nuanced approach, including an understanding of proper dosing, patient screening, and how to manage challenging emotional responses during treatment. Without this foundation, the risks of misuse or inadequate care could undermine the progress made so far.
Experts point to two main routes for a robust training program. The first integrates psychedelics into medical school curricula. The second offers specialized certification programs to clinicians already in practice. Whether healthcare institutions are ready to take that step remains unsettled.
A Call for Action
As public acceptance of psychedelics grows, the pressure is on the healthcare system to catch up. Ensuring that professionals are prepared to guide patients safely and effectively will be essential. For patients, the prospect of safe, evidence-based psychedelic therapy offers hope, but only if providers are equipped to meet the demand.
The pace of adoption in mental health care may depend on how quickly this knowledge gap closes. Training programs funded now will determine how many providers can offer these therapies once approvals arrive.
The Clinician Knowledge Gap in 2026
Survey after survey turns up the same split. Healthcare workers and clinicians report broad support for, or at least openness to, psychedelic-assisted therapy. The same respondents report low confidence in their own knowledge and limited formal training. A 2022 exploratory survey of psychiatrists at two professional conferences documented this mix of favorable opinion and self-rated knowledge gaps. Support and expertise are two different things. The distance between them is the real finding, and it has narrowed only slowly since these surveys began.
Clinicians act as gatekeepers here. Patients ask their doctor, nurse, or therapist before they ask anyone else. A provider who feels uninformed may struggle to explain realistic expectations, to screen for contraindications such as a personal or family history of psychosis, or to refer a patient to a legitimate program. Some of those patients then turn to forums and retreat marketing instead. Formal psychedelic education is still not standard in medical, nursing, or psychology curricula. Certificate programs run through universities and professional organizations, and enrollment is rising, but they reach a small fraction of the overall workforce.
The gap is becoming urgent rather than academic. Psilocybin is advancing toward possible FDA approval, Spravato is already in wide clinical use, and federal initiatives are expanding access. Each of those developments puts more clinicians in front of patients who have questions. Patients get better answers by asking a provider directly about their training and experience, rather than assuming familiarity with the topic. Providers who want to answer those questions well can close the gap through continuing education and established certificate programs.
Frequently Asked Questions
- Do doctors support psychedelic therapy?
- Surveys consistently find healthcare workers are broadly supportive of, or at least open to, psychedelic-assisted therapy. However, the same surveys find they report low confidence in their own knowledge and limited formal training. Support for the idea and expertise in the practice are two different things, and the gap between them is the central finding.
- Why do healthcare workers lack knowledge about psychedelics?
- Formal psychedelic education is still not standard in medical, nursing, or psychology curricula. Most clinicians trained before these therapies re-entered mainstream research, and continuing education on the topic is optional. Certificate programs exist through universities and professional organizations, but they reach a small share of the overall workforce.
- Why does the clinician knowledge gap matter for patients?
- Clinicians are usually the first people patients ask about new treatments. A provider who feels uninformed may not be able to explain risks and realistic expectations, screen for contraindications such as a psychosis history, or refer patients appropriately. That can leave patients relying on less reliable sources of information.
- How can I find a provider who understands psychedelic therapy?
- Do not assume a provider is informed on this topic, and ask directly about their training and experience. Look for clinicians who have completed formal psychedelic therapy training through recognized programs, and for those working in licensed programs or clinical research. Directories of verified providers can help narrow the search.
